These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17382258)

  • 1. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
    Giaccone L; Sorasio R; Patriarca F; Mattei D; Montefusco V; Peccatori J; Carnevale-Schianca F; Petrucci MT; Milone G; Guidi S; Rotta M; Fanin R; Corradini P; Boccadoro M; Bruno B
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):497-9. PubMed ID: 17382258
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
    Hattori N; Adachi D; Nakashima H; Saito B; Nakamaki T; Tomoyasu S
    Leuk Res; 2009 Apr; 33(4):574-7. PubMed ID: 18838167
    [No Abstract]   [Full Text] [Related]  

  • 4. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
    Kröger N; Zabelina T; Ayuk F; Atanackovic D; Schieder H; Renges H; Zander A
    Exp Hematol; 2006 Jun; 34(6):770-5. PubMed ID: 16728282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-threatening motor neurotoxicity in association with bortezomib.
    Gupta S; Pagliuca A; Devereux S; Mufti GJ; Schey S
    Haematologica; 2006 Jul; 91(7):1001. PubMed ID: 16757419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin lesions induced by bortezomib.
    Pour L; Hajek R; Zdenek A; Krejci M; Krivanova A; Vorlicek J
    Haematologica; 2005 Dec; 90(12 Suppl):ECR44. PubMed ID: 16464759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe epidermal necrolysis after bortezomib treatment for multiple myeloma.
    Fang B; Song Y; Ma J; Zhao RC
    Acta Haematol; 2007; 118(2):65-7. PubMed ID: 17505132
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple myeloma.
    Crawford CL
    N Engl J Med; 2005 Feb; 352(8):840-1; author reply 840-1. PubMed ID: 15736295
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
    Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
    J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newer treatment options for patients in first relapse. From the Multiple Myeloma Research Foundation.
    Richardson P
    Oncology (Williston Park); 2006 May; 20(6):633-8. PubMed ID: 16773847
    [No Abstract]   [Full Text] [Related]  

  • 12. [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
    Sanada Y; Nakazato T; Suzuki K; Mihara A; Aisa Y; Iwabuchi M; Kakimoto T
    Rinsho Ketsueki; 2010 Apr; 51(4):264-9. PubMed ID: 20467223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Berkowitz A; Walker S
    Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
    Mellstedt H; Gimsing P; Waage A
    Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
    [No Abstract]   [Full Text] [Related]  

  • 15. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
    Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
    J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
    Focosi D
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):E16-7. PubMed ID: 19717373
    [No Abstract]   [Full Text] [Related]  

  • 17. Subcutaneous bortezomib: a step towards optimised drug use.
    Mateos MV
    Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperlipidemia in a myeloma patient after bortezomib treatment.
    Gozzetti A; Fabbri A; Defina M; Chitarrelli I; Bocchia M
    Leuk Res; 2010 Sep; 34(9):e250. PubMed ID: 20363499
    [No Abstract]   [Full Text] [Related]  

  • 19. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 20. Genetic variation associated with bortezomib-induced peripheral neuropathy.
    Favis R; Sun Y; van de Velde H; Broderick E; Levey L; Meyers M; Mulligan G; Harousseau JL; Richardson PG; Ricci DS
    Pharmacogenet Genomics; 2011 Mar; 21(3):121-9. PubMed ID: 21228734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.